TRAINING IN LIFESPAN BEHAVIORAL, SOCIAL, AND NEUROSCIENCE RESEARCH CONNECTING EARLY-LIFE COGNITIVE DECLINE…
Federal financial assistance recorded from USAspending. This is not a procurement contract.
Assistance award details
- Assistance award identifier
- ASST_NON_K00AG068432_075
- FAIN
- K00AG068432
- Recipient
- PRESIDENT AND FELLOWS OF HARVARD COLLEGE
- Awarding agency
- Department of Health and Human Services
- Funding agency
- Department of Health and Human Services
- Assistance listing (CFDA)
- 93.866
- Total obligated
- $319,043
- Period
- Sep 1, 2020 – Aug 31, 2026
- Fiscal year
- 2022
- Place of performance state
- MA
- Source file
- FY2022_All_Assistance_Full_20261006.zip
Description
TRAINING IN LIFESPAN BEHAVIORAL, SOCIAL, AND NEUROSCIENCE RESEARCH CONNECTING EARLY-LIFE COGNITIVE DECLINE TO LATE-LIFE ADRD - ALZHEIMERâS DISEASE AND RELATED DEMENTIAS (ADRD) REPRESENT A GROWING HEALTH CONCERN AS THE GLOBAL POPULATION AGES. WHILE MANY PROMISING TREATMENTS FOR ADRD HAVE BEEN DEVELOPED AND TESTED, THEY HAVE LARGELY FAILED TO PREVENT DISEASE ONSET OR SLOW DISEASE PROGRESSION IN OLDER ADULTS. HOWEVER, RESEARCH HAS FOUND THAT SUBTLE SIGNS OF ADRD PATHOLOGY ARE DETECTABLE DECADES BEFORE DISEASE ONSET. TO DEVELOP TREATMENTS THAT CAN SLOW THE PROGRESSION OF ADRD BEFORE INTRACTABLE DETERIORATION OF THE BRAIN HAS TAKEN PLACE, WE WILL NEED TO BETTER UNDERSTAND THE LIFESPAN TRAJECTORY OF COGNITIVE, BIOLOGICAL AND BRAIN AGING AND DEVELOP BIOMARKERS THAT CAN CONNECT SUBTLE SIGNS OF INDIVIDUAL DIFFERENCES IN MIDLIFE AGING TO ADRD IN LATE LIFE. IN THE F99 PHASE OF THE PROPOSED RESEARCH, THE CANDIDATE WILL CHARACTERIZE SIGNATURES OF MIDLIFE BRAIN AGING AND INVESTIGATE POTENTIAL SURROGATE BIOMARKERS USING A MULTI-FACETED APPROACH IN THE DUNEDIN STUDY, A POPULATION REPRESENTATIVE BIRTH COHORT NOW IN MIDLIFE. SPECIFICALLY, THE CANDIDATE WILL INVESTIGATE THE ABILITY OF WIDELY USED MEASURES OF RISK FOR ADRD IN OLDER ADULTS, INCLUDING WHITE MATTER HYPERINTENSITIES AND BRAIN AGE, TO MEASURE ACCELERATED COGNITIVE AND BIOLOGICAL AGING IN MIDLIFE. THE CANDIDATE WILL THEN DEVELOP A LONGITUDINAL MEASURE FROM 20 YEARS OF BIOLOGICAL AGING ACROSS 19 BIOMARKERS TO INVESTIGATE THE CONSEQUENCES OF ACCELERATED PACE OF BIOLOGICAL AGING ON INDIVIDUAL DIFFERENCES IN THE STRUCTURAL INTEGRITY OF THE BRAIN IN MIDLIFE. THEN THE CANDIDATE WILL USE CHILDHOOD EXPOSURE TO THE NEUROTOXIN LEAD, A KNOWN RISK FACTOR FOR ADRD, TO FURTHER EXAMINE THE UTILITY OF THESE CANDIDATE SURROGATE BIOMARKERS TO CAPTURE RISK-RELATED FEATURES OF MIDLIFE BRAIN AGING. IN THE K00 PHASE OF THE PROPOSED RESEARCH, THE CANDIDATE WILL UTILIZE STATISTICAL TECHNIQUES, DEVELOPED WHEN CREATING THE PACE OF BIOLOGICAL AGIN